All News

exercise,group

Faith in Exercise Benefit Boosts Actual Benefit in SpA

d MedPage Today

Patients with axial spondyloarthritis (SpA) got more bang for their exercise buck in a randomized trial when they had good opinions about their workout program, with better persistence with exercise at 1 year relative to a control group, researchers said.

Read Article
mediterraneansandwich-498379__180.jpg

Dietary Improvement in Psoriatic Arthritis

d Jack Cush, MD

The results of the DIETA trial showed that dietary changes may control psoriatic arthritis (PsA) disease activity, independent of weight loss.  

Read Article
TNR,PSA,journal,0412

Now Available: TNR - Psoriatic Arthritis Journal Club

d Jack Cush, MD

A recording of this week’s Tuesday Night Rheumatology is now available. This outstanding webinar featured a robust discussion of the EXCEED study and Discover-2 trial, with Drs. Philip Mease, Peter Nash, Jack Cush and Rachel Tate.

Read Article
Beijing #RA Cohort study compared 102 T2T (CENTRA) vs 271 usual care pt (TARRA) groups for SDAI outcomes at 12 mos. CENTRA had signif lower SDAI than TARRA (2.1 vs 3.4; p<0.001) & more SDAI-defined remission (71% vs 49%; p<0.001) https://t.co/1JBP33eifI https://t.co/RmGny30QAq

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - PsA Lessons from the Clinic What are the Safe Treatment Options for psoriatics who have HIV? QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/fh00ydSYd3 https://t.co/fpDl2tF4cw

Links:

Dr. John Cush RheumNow ( View Tweet)
Miss this blog from earlier in the month? Dr. Eric Ruderman ( @jointMD) weighs in on combined clinics for PsA and its value. https://t.co/4mdjmetGvF https://t.co/nJJXmk0a0t

Links:

Dr. John Cush RheumNow ( View Tweet)
ABP 654 is a Ustekinumab (anti-IL-12/23) biosimilar from Amgen - 563 pt, phase 3 trial shown to be equivalent to originator in mod- severe plaque psoriasis (no meaningful differences). ABP 654 is also being developed for Crohns & UC. https://t.co/vDNfMXCWcC

Links:

Dr. John Cush RheumNow ( View Tweet)

Italian retrospective of Canakinumab in 80 kids w/ Systemic JIA - 12 moved from anakinra to CAN w/ iinactive dz/CID. 58 pts w/ active SoJIA started CAN - CID in 57% at 6mos, 64% 12 mos; MAS 3/100PY; Nonresp assoc w/ MAS, #Jts, Dz duration https://t.co/2YmkukU7Z2

Links:

Dr. John Cush RheumNow ( View Tweet)

Open label, RCT compared triple DMARD Rx adding either LEF (MLH) or SSZ (MSH) to MTX+HCQ in 136 RA pts. Both were equally effective (non-inferior), 61.7% & 64.7% patients (p = 0.8) at wk 24. AE were also equal (15 vs 21 AE). https://t.co/cxdeBfo6XA

Links:

Dr. John Cush RheumNow ( View Tweet)

2 studies from NKF meeting shows gout occurs in 13.5% of CKD on dialysis; and seen in 17-28% of Stg 3,4 CKD pts. CKD w/ Gout has more bone/mineral Dz (40 vs 26%), CHF (21 vs 14%), DJD (17 vs 9%); >1/3 NOT on urate lowering therapy https://t.co/sn40xqxRyg https://t.co/ewb0tpWukw

Links:

Dr. John Cush RheumNow ( View Tweet)

Can IL-22 differentiate between IL-17 & TNF inhibitor #PSA responders? Pilot study 2 cohorts 81 PSA pts showed both biologics worked but somewhat better response in IL-17i Pts w/ low IL- & TNFi responses w/ high IL-22 levels. https://t.co/txyNl2OwTP

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Copenhagen study of COVID & Rheum disease (AIRD) ▶️ COVID+ AIRD pts have 10x more hospitalizations (7% vs 0.7%) ▶️ Only RTX assoc w/ COVID hosp (adj OR 14.6) ▶️ IgG Abs increased if AIRD pt hospitalized https://t.co/VtERRZsGb8 https://t.co/ZwdfNJaAS7

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Males respond better than females? Ixekizumab trials in #PSA - 676 pts in Two Phase 3 RCTs - females had lower response rates than males in all measures (ACR20/50/70; MDA; DAPSA) F had ⬆️HAQ, enthesitis, but ⬇️CRP https://t.co/sjVJZ8uQA3 https://t.co/l7B2ICZWaJ

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: SLE study from BC, Canada shows that among 3062 incident #SLE patients 96% received antimalarial (AM) Rx with only 40% adherent. Over a 6.4 yr F/U, 242 (8%) died. AM adherence was assoc w/ a 71% and 83% lower risk of death https://t.co/0uKAKJVxri https://t.co/KuvEA2pzrg

Links:

Dr. John Cush RheumNow ( View Tweet)
In #rheumatology ,the longer you see pts,the more they rely on you for issues related to their disease, including ➡️ Dental/mental Health ➡️ Nutrition/exercise/sleep ➡️ PT/OT/rehab Looking for resources pertaining to rheumatology to self educate. #RheumTwitter #MedTwitter

Tanmayee Bichile, MD BichileT ( View Tweet)

Register for Tuesday Night Rheumatology today! Join us as we discuss the controversies in PsA when it comes to diagnosis, treatment strategies, therapeutics and more. https://t.co/YXAmzvPfeK https://t.co/jtSd0Ig5IT

Links:

Dr. John Cush RheumNow ( View Tweet)
Administrative Claims data from British Columbia studied 100,358 OA pts and compared tramadol v NSAIDs. Tramadol was associated with higher All-cause mortality (HRs,1.2 to 1.5), more VTE (v diclofenac, HR 1.7), more hip Fx (HR 1.6) https://t.co/5Lei6Lgtpf

Links:

Dr. John Cush RheumNow ( View Tweet)

Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor https://t.co/CfAjvc9XWg https://t.co/RaD5qqPM3a

Links:

Dr. John Cush RheumNow ( View Tweet)
No Benefit to More Intensive Urate Lowering in Gout While treat-to-target (T2T) is commonly advocated in gout management, it is unknown if T2T (or more intensive T2T) may result in less bony erosions in gout. https://t.co/uag4fJ4FSi https://t.co/djniwFl491

Links:

Dr. John Cush RheumNow ( View Tweet)
Copenhagen study of COVID & Rheum disease (AIRD) ▶️ COVID+ AIRD pts have 10x more hospitalizations (7% vs 0.7%) ▶️ Only RTX assoc w/ COVID hosp (adj OR 14.6) ▶️ IgG Abs increased if AIRD pt hospitalized https://t.co/WYXbt2FJJi https://t.co/K2NGJsKVVc

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×